We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Events

16 Nov 2026 - 19 Nov 2026
08 Dec 2026 - 10 Dec 2026

Glucosamine Equal to Placebo in Treating Lower Back Pain

By HospiMedica International staff writers
Posted on 19 Jul 2010
A new study has found that glucosamine is no better than placebo at reducing pain-related disability in people suffering from lower back pain (LBP) due to degenerative lumbar osteoarthritis (OA).

Researchers at Oslo University Hospital (OUH; Norway) conducted a double blind, randomized, placebo-controlled trial with 250 participants aged over 25, who were recruited from outpatients attending the OUH outpatient clinic who had been experiencing LBP for more than six months, together with degenerative lumbar OA. More...
The participants were randomized to two groups of 125 patients; one group took 1,500 mg of glucosamine supplement every day for 6 months, and the other group took a placebo. The patients underwent assessment at baseline, and then at fixed time points during the six month period, and again at one year. All patients completed the Roland Morris Disability Questionnaire (RMDQ) about their quality of life, level of disability, and levels of pain experienced during rest and activity.

The researchers found that at baseline, mean RMDQ scores were 9.2 for the glucosamine and 9.7 for the placebo group. At 6 months, the mean RMDQ score was the same for both groups; at one year, the mean RMDQ scores were 4.8 for glucosamine and 5.5 for the placebo group. No statistically significant difference in change between groups in RMDQ, LBP, or quality of life was found when assessed after the 6-month intervention period and at one year. Mild adverse events were reported in 40 patients in the glucosamine group and 46 in the placebo group. The study was published in the July 7, 2010, issue of the Journal of the American Medical Association (JAMA).

"Among patients with chronic LBP and degenerative lumbar OA, 6-month treatment with oral glucosamine compared with placebo did not result in reduced pain-related disability after the 6-month intervention and after 1-year follow-up,” concluded lead author Philip Wilkens, M.Chiro., and colleagues of the department of orthopedics.

Glucosamine is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids, and is one of the most common nonvitamin, nonmineral, dietary supplements used by adults. Glucosamine is part of the structure of the polysaccharides chitosan and chitin, which compose the exoskeletons of crustaceans and other arthropods, cell walls in fungi, and many higher organisms. It is produced commercially by the hydrolysis of crustacean exoskeletons or, less commonly by fermentation of a grain such as corn or wheat.

Related Links:

Oslo University Hospital



Gold Member
Blood Gas Analyzer
i-Check200
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Syringe Pump
SP50 Series
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: A view inside the custom virtual reality environment used in the study: a calm room with a teddy bear, soft colors and large windows looking out over the sea. (Image Credit: Walaa S. Abu Rukbah et al., Virginia Commonwealth University; CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)

Virtual Reality Program May Reduce Anxiety Before Pediatric Surgery

Presurgery anxiety affects an estimated 50% to 75% of children undergoing surgery and can complicate anesthesia induction, increase postoperative pain, and prolong recovery. Sedation is often used to manage... Read more

Medical Imaging

view channel
Image Credit: Adobe Stock

Lung Ultrasound Predicts Progression of Interstitial Lung Abnormalities in Rheumatoid Arthritis

Interstitial lung abnormalities are a pulmonary concern in patients with rheumatoid arthritis, requiring monitoring to detect disease progression. However, tracking these changes often involves repeated... Read more

Point of Care

view channel
Image: Fluorescence image of water-acetone mixture condensation. (Photo courtesy of Jingcheng Ma/Interfacial Thermofluids Laboratory)

New Breath Condensate Testing Approach Enhances Reliability for COPD Monitoring

Chronic obstructive pulmonary disease (COPD) is a progressive lung condition that can increasingly impair breathing over time. Diagnosis and monitoring may be burdensome because patients often require... Read more

Business

view channel
Image: Stryker has acquired ZuriMED, adding the FiberLocker System, a rotator cuff augmentation technology designed to strengthen repairs, to its Sports Medicine portfolio. (Photo courtesy of ZuriMED)

Stryker Completes Acquisition to Broaden Shoulder Surgery Offerings

Stryker (Portage, MI, USA) has completed its acquisition of ZuriMED (Zurich, Switzerland), a privately held developer of the FiberLocker System, expanding its Sports Medicine portfolio with a commercialized... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.